BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35180650)

  • 1. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
    Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
    Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
    Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos F; Walter B; Otto W; Burger M; Erlmeier M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S;
    Urol Int; 2023; 107(7):713-722. PubMed ID: 37348477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cMET: a prognostic marker in papillary renal cell carcinoma?
    Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S;
    Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
    Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
    Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudins as prognostic factors for renal cell cancer.
    Virman J; Soini Y; Kujala P; Luukkaala T; Salminen T; Sunela K; Kellokumpu-Lehtinen PL
    Anticancer Res; 2014 Aug; 34(8):4181-7. PubMed ID: 25075044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of claudins 1, 4, and 7 and their prognostic significance in nasopharyngeal carcinoma.
    Suren D; Yildirim M; Kaya V; Elal R; Selcuk OT; Osma U; Yildiz M; Gunduz S; Sezer C
    J BUON; 2015; 20(1):212-7. PubMed ID: 25778318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers.
    Merikallio H; Pääkkö P; Harju T; Soini Y
    Int J Clin Exp Pathol; 2011; 4(7):667-73. PubMed ID: 22076167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
    Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
    In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information.
    Yu W; Zhang W; Jiang Y; Wang Y; Li Y; Wang J; Sun L; Ran W; Li H
    Acta Histochem; 2013 Jun; 115(5):452-9. PubMed ID: 23219441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
    Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
    BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma.
    Ge L; Chen W; Cao W; Liu G; Zhang Q; Zhuang J; Zhang M; Yang J; Guo S; Zhao X; Guo H
    Cancer Biomark; 2018; 22(3):395-403. PubMed ID: 29865032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.